Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102577 | 0.87 | MEN1 (0.34) | MEN1KMT2AMAPK1CYP2C9DGAT1 | |
| SCHEMBL20102612 | 0.86 | SPHK1 (0.36) | MEN1KMT2AMAPK1CYP2C9MAPT | |
| SCHEMBL20102581 | 0.86 | DGAT1 (0.36) | DGAT1MAPTGAA | |
| SCHEMBL4401705 | 0.86 | CYP2C9 (0.39) | MEN1KMT2AMAPK1CYP2C9DGAT1 | |
| SCHEMBL22277193 | 0.85 | CYP2C9 (0.38) | MEN1KMT2AMAPK1CYP2C9DGAT1 | |
| SCHEMBL20102584 | 0.85 | FASN (0.33) | — | |
| SCHEMBL20102479 | 0.84 | OPRL1 (0.37) | MEN1KMT2AMAPTGAA | |
| SCHEMBL20111334 | 0.84 | DGAT1 (0.34) | MEN1KMT2AMAPK1CYP2C9DGAT1 | |
| SCHEMBL22881576 | 0.83 | CYP2C9 (0.39) | MEN1KMT2AMAPK1CYP2C9DGAT1 | |
| SCHEMBL20102609 | 0.82 | SPHK1 (0.37) | CYP2C9SPHK1CYP3A4CYP2C8S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | MEN1 2571/4885KMT2A 2759/4885MAPK1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.